University of New Mexico Health Sciences Center | UNM Cancer Center Clinical Research Office/NMCCA

Research site

(Unclaimed)

Location

1201 Camino de Salud Northeast, Albuquerque, New Mexico, United States of America

Site insights

Top conditions

Top treatments

Ritlecitinib

Treprostinil

Seralutinib

Psilocybin

Levodopa

Fesoterodine

Nalmefene

ADX48621

Tirzepatide

Metformin

Parent organization

This site is a part of University of New Mexico Health Sciences Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 84 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (Tranquillo LTE)

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling

Vitiligo

Drug: Ritlecitinib

Drug: Ritlecitinib 100 mg

New

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effec...

Begins enrollment this month

Parkinson Disease

Other: Placebo

Drug: AP-472

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (SERANATA)

This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE...

Enrolling

Pulmonary Hypertension Associated With Interstitial Lung Disease

Device: Generic Dry Powder Inhaler

Drug: Placebo

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis...

Invitation-only

Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Device: Treprostinil Ultrasonic Nebulizer

Drug: Inhaled Treprostinil

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients (CTN0121)

The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervent...

Active, not recruiting

Substance Use Disorders

Injection Site Infection

Behavioral: Treatment as Usual

Behavioral: SIRI Team

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have comp...

Active, not recruiting

Pulmonary Arterial Hypertension

Device: Gereic Dry Powder Inhaler

Drug: Seralutinib

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor 50 MG

Drug: Placebo